Showing results (261-270 of 285) with videos related to

Sort By:
Pageof 29
Nature Communications|January 18, 2025
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosisAndreas Römpp, Axel Treu, Julia Kokesch-Himmelreich, et al.
British Journal of Clinical Pharmacology|November 28, 2022
The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trialAlexander J Robbins, Nur Amalina Che Bakri, Edward Toke-Bjolgerud, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2012
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamidesDenis R St Laurent, Makonen Belema, Min Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B CellsElizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, et al.
Nature|November 5, 2015
Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5AJin-Hua Sun, Donald R O'Boyle, Robert A Fridell, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2017
Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymeraseBarbara Zhizhen Zheng, Stanley V D'Andrea, Umesh Hanumegowda, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 2013
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologiesOmar D Lopez, Van N Nguyen, Denis R St Laurent, et al.
ACS Medicinal Chemistry Letters|July 26, 2017
Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase InhibitorKyle Parcella, Kyle Eastman, Kap-Sun Yeung, et al.
Pageof 29